Drugs / NIM811
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00983060 | Sep 2009 → Apr 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-04-16 | Scynexis, Inc. | Results SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class scynexis.com ↗
The study suggests that hyperbilirubinemia liver toxicity is not a class effect, but may be the result of drug-mediated MRP2 inhibition. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-04-16 | Scynexis, Inc. | SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class scynexis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIM811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00983060 ↗ |
| Action | Inhibit | “NIM811, a novel, non-immunosuppressive cyclophilin inhibitor was studied in ascending doses” PMID 21255610 ↗ Jan 2011 |
| Modality | Protein / enzyme biologic | — CHEMBL1688529 ↗ |
| Route | Oral | “Doses of 10 up to 600 mg were given orally once or twice daily” PMID 21255610 ↗ Jan 2011 |